已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Catheter-Directed Thrombolysis vs Anticoagulation in Patients With Acute Intermediate-High–risk Pulmonary Embolism

医学 肺栓塞 溶栓 内科学 外科 心脏病学 心肌梗塞
作者
Parham Sadeghipour,Yaser Jenab,Jamal Moosavi,Kaveh Hosseini,Bahram Mohebbi,Ali Hosseinsabet,Saurav Chatterjee,Hamidreza Pouraliakbar,Shapour Shirani,Mehdi H. Shishehbor,Azin Alizadehasl,Melody Farrashi,Mohammad Ali Rezvani,Farnaz Rafiee,Arash Jalali,Sina Rashedi,Omid Shafe,Jay Giri,Manuel Monréal,David Jiménez
出处
期刊:JAMA Cardiology [American Medical Association]
卷期号:7 (12): 1189-1189 被引量:116
标识
DOI:10.1001/jamacardio.2022.3591
摘要

Importance: The optimal treatment of intermediate-high-risk pulmonary embolism (PE) remains unknown. Objective: To assess the effect of conventional catheter-directed thrombolysis (cCDT) plus anticoagulation vs anticoagulation monotherapy in improving echocardiographic measures of right ventricle (RV) to left ventricle (LV) ratio in acute intermediate-high-risk PE. Design, Setting, and Participants: The Catheter-Directed Thrombolysis vs Anticoagulation in Patients with Acute Intermediate-High-Risk Pulmonary Embolism (CANARY) trial was an open-label, randomized clinical trial of patients with intermediate-high-risk PE, conducted in 2 large cardiovascular centers in Tehran, Iran, between December 22, 2018, through February 2, 2020. Interventions: Patients were randomly assigned to cCDT (alteplase, 0.5 mg/catheter/h for 24 hours) plus heparin vs anticoagulation monotherapy. Main Outcomes and Measures: The proportion of patients with a 3-month echocardiographic RV/LV ratio greater than 0.9, assessed by a core laboratory, was the primary outcome. The proportion of patients with an RV/LV ratio greater than 0.9 at 72 hours after randomization and the 3-month all-cause mortality were among secondary outcomes. Major bleeding (Bleeding Academic Research Consortium type 3 or 5) was the main safety outcome. A clinical events committee, masked to the treatment assignment, adjudicated clinical outcomes. Results: The study was prematurely stopped due to the COVID-19 pandemic after recruiting 94 patients (mean [SD] age, 58.4 [2.5] years; 27 women [29%]), of whom 85 patients completed the 3-month echocardiographic follow-up. Overall, 2 of 46 patients (4.3%) in the cCDT group and 5 of 39 patients (12.8%) in the anticoagulation monotherapy group met the primary outcome (odds ratio [OR], 0.31; 95% CI, 0.06-1.69; P = .24). The median (IQR) 3-month RV/LV ratio was significantly lower with cCDT (0.7 [0.6-0.7]) than with anticoagulation (0.8 [0.7-0.9); P = .01). An RV/LV ratio greater than 0.9 at 72 hours after randomization was observed in fewer patients treated with cCDT (13 of 48 [27.0%]) than anticoagulation (24 of 46 [52.1%]; OR, 0.34; 95% CI, 0.14-0.80; P = .01). Fewer patients assigned to cCDT experienced a 3-month composite of death or RV/LV greater than 0.9 (2 of 48 [4.3%] vs 8 of 46 [17.3%]; OR, 0.20; 95% CI, 0.04-1.03; P = .048). One case of nonfatal major gastrointestinal bleeding occurred in the cCDT group. Conclusions and Relevance: This prematurely terminated randomized clinical trial of patients with intermediate-high-risk PE was hypothesis-generating for improvement in some efficacy outcomes and acceptable rate of major bleeding for cCDT compared with anticoagulation monotherapy and provided support for a definitive clinical outcomes trial. Trial Registration: ClinicalTrials.gov Identifier: NCT05172115.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
sanqian完成签到 ,获得积分10
2秒前
星星完成签到 ,获得积分10
3秒前
3秒前
3秒前
墨鱼君爱摸鱼完成签到,获得积分10
5秒前
潇1010完成签到,获得积分10
6秒前
张哈哈完成签到 ,获得积分10
6秒前
小象完成签到,获得积分0
7秒前
013完成签到,获得积分10
7秒前
zyy发布了新的文献求助10
8秒前
爱you发布了新的文献求助10
8秒前
奇点完成签到 ,获得积分10
8秒前
野心大大滴完成签到,获得积分10
9秒前
炙热尔阳完成签到 ,获得积分10
9秒前
12秒前
FadedTulips完成签到 ,获得积分10
13秒前
xinyuanjia的应助被一彤展翅采纳,获得30
14秒前
联联完成签到 ,获得积分10
15秒前
健康的紫文完成签到,获得积分10
15秒前
16秒前
16秒前
16秒前
小菜鸡完成签到,获得积分10
19秒前
奇迹发布了新的文献求助10
22秒前
ella333发布了新的文献求助30
23秒前
风中的宛白的应助被hulai采纳,获得10
23秒前
25秒前
烟花的应助被area采纳,获得10
25秒前
慕青的应助被黎明采纳,获得10
25秒前
Parsee的应助被卤一碗芋头糕采纳,获得10
27秒前
季夏聆风吟完成签到 ,获得积分10
28秒前
李金成完成签到 ,获得积分20
30秒前
32秒前
乐羽乐完成签到,获得积分10
33秒前
Luo完成签到 ,获得积分10
33秒前
34秒前
ella333完成签到,获得积分10
34秒前
area发布了新的文献求助10
37秒前
流萤晓成眠完成签到,获得积分10
37秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179547
求助须知:如何正确求助?哪些是违规求助? 9569910
关于积分的说明 21807373
捐赠科研通 7775016
什么是DOI,文献DOI怎么找? 3433072
关于科研通互助平台的介绍 2556999
邀请新用户注册赠送积分活动 2478760